Shares of Abeona Therapeutics plunged more than 45% in early morning trading on April 23 after the Company disclosed receiving a Complete Response Letter from the U.S. Food and Drug Administration for its lead clinical program pz-cel.
Contact our attorneys for a no-cost case evaluation.